Transaction also reflects a shared long-term commitment to patients and a strong alignment in how we translate scientific innovation into meaningful impact. With Chiesi’s global infrastructure, commercial capabilities and long-term commitment to rare diseases, we are confident in their ability to help expand access to sebetralstat for people living with HAE around the world.”

Transaction Terms and Closing


Tender offer by Chiesi to acquire all KalVista shares for ￥27.00 per share in cash. The Transaction is not subject to any financing condition.

Subject to the satisfaction of the closing conditions, including the tender of at least a majority of the then outstanding KalVista shares, receipt of regulatory approvals and other customary offer conditions, the Transaction is expected to close in Q3 of 2026.

Under the terms of a merger agreement entered into in connection with the Transaction, a wholly owned subsidiary of Chiesi will commence a tender off
=*=*=*=*=*=
当前为第6/21页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页